Geron Corporation (GERN)
| Bid | 1.37 |
| Market Cap | 904.42M |
| Revenue (ttm) | 76.99M |
| Net Income (ttm) | -174.57M |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | -5.26 |
| Forward PE | 70.5 |
| Analyst | Buy |
| Ask | 1.43 |
| Volume | 6,174,196 |
| Avg. Volume (20D) | 15,536,873 |
| Open | 1.40 |
| Previous Close | 1.41 |
| Day's Range | 1.34 - 1.43 |
| 52-Week Range | 1.17 - 5.34 |
| Beta | 0.66 |
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...
Analyst Forecast
According to 8 analyst ratings, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 181.69% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
41 minutes ago · accessnewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERNNEW YORK, NY / ACCESS Newswire / May 1, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws,...
